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A synthetic peptide corresponding to rubella virus capsid protein residues 263 to 275 which contains an epitope recognized
by a cloned CD4/ cytotoxic T-lymphocyte (CTL) line was used to induce CD8/ T-cell lines specific to this peptide. A peptide-
specific CD8/ CTL clone was derived and characterized. This peptide-specific CD8/ CTL clone exhibited cytotoxicity against
target cells infected by a vaccinia recombinant virus expressing rubella virus capsid protein, but not by target cells infected
by vaccinia recombinant virus expressing rubella virus E1 or E2 envelope proteins. Analysis of HLA class I restriction of
the CD8/ CTL clone revealed that A11 and A3 were restrictive elements. Fine mapping with truncated and overlapping
peptide analogs revealed a nonamer sequence, C(264-272), as the T-cell epitope eliciting stronger cytotoxicity. Two anchor
residues for binding to HLA A11 and A3 were identified at position 2 (isoleucine) and at position 9 (histidine) or at position
8 (arginine) of the epitope sequence. The identification of overlapping CD4/ and CD8/ T-cell epitopes within the capsid
protein sequence C(263–275) implicates a strategy for using such epitopes in a candidate peptide-based rubella vaccine.
q 1997 Academic Press
INTRODUCTION three structural proteins: the envelope glycoproteins (E1
and E2) located on the virion surface and a capsid protein
Rubella virus (RV) infection during pregnancy may re-
(C) in the RNA core (Oker-Blom et al., 1983; Clarke et al.,
sult in spontaneous abortion or severe birth defects (San-
1987). Four nonoverlapping domains which are binding
dra et al., 1985). Live, attenuated RV vaccines which have sites for RV-neutralizing antibodies have been located
been used since 1969 to immunize infants and suscepti- within amino acids residues 213 to 285 on RV E1 protein
ble women of child-bearing age have successfully re- (Terry et al., 1988; Lozzi et al., 1990; Wolinsky et al., 1991,
duced disease incidence (Perfins, 1985). Nevertheless, 1993; Chaye et al., 1992a; Mitchell et al., 1992). Several
there are still medical concerns such as primary or sec- immunodominant T-cell epitopes within RV proteins E1,
ondary vaccine failure and RV vaccine-associated arthri- E2, or C and their human leukocyte antigen (HLA) restric-
tis. Transient arthritis is common in adult female vaccin- tive characteristics have also been identified (Ou et al.,
ees. RV vaccine-associated arthritis occurs acutely in 1992a,b,c, 1993, 1994, 1996; Lovett et al., 1993; McCarthy
approximately 5% of previously seronegative adult fe- et al., 1993; Mitahell et al., 1993; Marttila et al., 1996). The
males receiving the currently used live attenuated RA27/ importance of cytotoxic T lymphocytes (CTLs) in antiviral
3 strain of RV vaccine (Chantler et al., 1982; Tingle et al., immunity is well documented (Quinnan et al., 1982;
1997). Of those affected, some (about 1%) will develop McMichael et al., 1983; Rouse et al., 1988; Raychaudhuri
chronic and debilitating joint manifestations (Chantler et et al., 1993). Although the role of rubella virus-specific
al., 1982; Fraser et al., 1983; Sandra et al., 1985; Tingle CTL in protective immunity is currently unknown, Lovett
et al., 1997). Hence, there is an indication for the develop- et al. have identified an HLA A2-restricted epitope by
ment of a less reactogenic second-generation vaccine CTL cell lines induced by RV-infected fibroblasts. This
(such as peptide, recombinant protein, or modified atten- epitope is located within residues 1–29, at the N-terminal
uated virus) suitable for use in women. Ideally, this vac- of RV C protein (Lovett et al., 1993).
cine would employ only antigenic regions known to give Soluble proteins and synthetic peptides are generally
rise to protective immunity. poor immunogens for in vitro induction of CD8/, class I-
Before using synthetic peptides as components of a restricted antigen-specific T cells. However, in the study
RV subunit vaccine, it is essential to identify the relevant reported here, a rubella virus capsid peptide, C(263–
antigenic sites for RV-specific T lymphocytes and anti- 275), which contains a previously identified CD4/ T-cell
bodies (Milich, 1988; Milich et al., 1988). RV contains epitope (Ou et al., 1992a,b), also gave rise to specific
CD8/ CTL clones. The T-cell epitope within this peptide
recognized by both CD4/ and CD8/ clones has been1 To whom reprint requests should be addressed. Fax: (604) 875-
2496. characterized.
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MATERIALS AND METHODS Immunology, Ontario, Canada) as described previously
(Ou et al., 1996).
Synthetic Peptides
EBV-transformed B-cell lines (EBV-BLs)
Peptides encompassing capsid protein residues
EBV-BLs were established earlier in our laboratoryC(261–277) (TTERIETRSARHPWRIR) and C(263–275) of
from HLA heterologous donors (Ou et al., 1992b). TheseRV M33 strain (Clarke et al., 1987) and single amino
EBV-BLs expressing different HLA class I and class IIacid substituted analogs of RV peptide C(265–273) were
phenotypes were used as targets in 51Cr release assays.synthesized in an automated ABI 430A peptide synthe-
sizer using standard solid-phase methods.
Vaccinia recombinant viruses
RV-specific T-cell clones Recombinant plasmids were constructed by subclon-
ing the RV cDNAs encoding C, E2, or E1 structural protein
The T-cell clones ATC11A and ATCGC used for this
into the SmaI site of the plasmid pGS20 (Mackett et al.,
study were derived from a RV seropositive donor (AT) ex-
1984; Hobman et al., 1990). Vaccinia virus recombinants
pressing HLA A3, A11, DRB1*0403, and DRB1*0701 phe-
were isolated essentially as described by Mackett et al.
notypes, using the method described previously (Ou et
(1984). Analysis of expressed proteins from the recombi-
al., 1992b, 1994, 1996). Briefly, peripheral blood mononu-
nant virus was carried out by the method described pre-
clear cells (PBMNC) were incubated with peptide C(261 –
viously (Hobman et al., 1990; Chaye et al., 1992b). Vac-
277) for deriving clone ATC11A or with peptide C(263 –
cinia virus (WR strain; American Type Culture Collection,
275) for deriving clone ATCGC at a final concentration
Rockville, MD) was used as a negative control.
of 10 mM in a complete medium [RPMI 1640 containing
2 mM L-glutamine, 25 mM N-2-hydroxyethylpiperazine- Cytotoxicity assay
N*-2-ethanesulfonic acid (HEPES), 50 mM penicillin, 50
Standard 51Cr release assays were used to measuremM streptomycin, and 5 1 1005 M 2-mercaptoethanol
CTL responses (Ou et al., 1994, 1996). For use as CTL(2-ME)] supplemented with 10% autologous plasma.
targets, EBV-BL cells (1 1 106 cells) were sensitized byStarting on the fifth day of incubation at 377, 10 U/ml
incubating at 377 for 1 hr with peptide at a final concentra-of human recombinant interleukin-2 (rIL2) (GIBCO/BRL,
tion of 10 mM in complete RPMI medium. Also EBV-BLGaithersburg, MD) was added into culture every 3 days.
cells (1 1 106 cells) were infected with vaccinia recombi-After 14 days, cells were tested in proliferation assays
nant viruses or wild-type vaccinia virus (negative control)for their recognition of the peptide C(263–275). Peptide-
at 10 PFU/cell for 1 hr, washed three times, and thenreactive lymphocytes were subsequently cloned by lim-
incubated overnight. After peptide sensitization or virusiting dilution in 96-well round-bottom plates (Nunc, Den-
infection, 1 1 106 cells were washed once with completemark) at 0.3 cell per well in a complete medium sup-
medium and internally labeled for 1 hr at 377 with 100 mCiplemented with 10% human AB serum (Sigma, Oakville,
of Na2
51CrO4 (Amersham, Ontario, Canada). RadiolabeledCanada) instead of autologous plasma, 10 U/ml of rIL2,
target cells were washed four times with medium and10 mM peptide C(263–275), 5% Lymphocult-T-LF (Biotest,
then incubated for 4 hr at 377 with T cells at differentDreieich, Germany), and g-irradiated (2500 rad) autolo-
effector/target ratios in round-bottomed 96-well platesgous PBMNC (5 1 104/well). After 7 days, all wells were
(Nunc). All assays were performed in triplicate. Percent-supplemented with complete medium containing 5%
age specific cytotoxicity was calculated by the formula:Lymphocult-T-LF and 20 U/ml rIL2. By Days 10–12,
100 [(ER-SR)/(MR-SR)], where ER (experimental 51Cr re-clones were discernible microscopically. Each clone was
lease) is the mean counts per minute released into thetransferred into fresh medium in a 4-well plate (Nunc)
supernatant in the presence of T cells, using 5 1 103/and restimulated with peptide with the presence of g-
well target cells, SR (spontaneous 51Cr release) is theirradiated autologous PBMNC. T-cell clones (2 1 105
mean counts per minute in the absence of T cells deter-cells/ml) were maintained in culture by stimulating at
mined in four replicate samples, and MR (maximal 51Crweekly intervals T cells with peptide C(261–277) (clone
release) is the mean counts per minute in supernatantATC11A) or peptide C(263 –275) (clone ATCGC) at a con-
of target cells incubated with 0.5% Nonidet-P40 (NP-40)centration of 10 mM in the presence of 11 106/ml autolo-
detergent (Sigma, St. Louis, MO) determined in four repli-gous, g-irradiated PBMNC. Cultures were replenished
cates. SR was always 25% of MR.every 3 to 5 days with complete RPMI medium containing
2 mM L-glutamine, 25 mM HEPES, 50 IU/ml penicillin, 50
Murine anti-human HLA class I or II monoclonal
mg/ml streptomycin, 5 1 1005 M 2-ME, 10% human AB
antibodies (mAbs)serum, 20 U/ml rIL-2, and 5% Lymphocult-TL-F. The T-
cell clones were phenotyped by flow cytometry using In order to define HLA class I or II restriction on the
CTL clones, anti-HLA mAbs were used to inhibit cytotoxicmonoclonal anti-CD4 and anti-CD8 antibodies (Coulter
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BL AT, autologous to the T-cell clone. This T-cell clone
is restricted promiscuously by DR4, DR9, and DR53 (Ou
et al., manuscript in preparation). Several CTL clones
were recently derived from a RV-specific T-cell line in-
duced by peptide C(263–275) from the same donor as
the CD4/ clone ATC11A. The clones were tested for
C(263–275) specificity in 51Cr release cytotoxicity assays,
using EBV-BL AT cells sensitized with the peptide C(263–
275) as targets. The CD4/CD8 phenotype of these cells
was established by flow cytometric analysis. The results
revealed that some of these clones expressed the CD8
phenotype and others expressed the CD4 phenotype. To
rule out the possibility that the CTL activity observed was
mediated by contaminating CD4/ T cells in these CD8/
clones, we repeatedly verified the phenotype of such a
clone, ATCGC, which was initially 98% CD8/ cells. We
tested it periodically during the 2–4 months over which
experiments were performed and confirmed that the
cloned population remained 98% CD8/ cells.
FIG. 1. Specific cytotoxicity of CD4/ T-cell clone ATC11A to target Generally, CD8/ T cells recognize only endogenously
cells sensitized by RV capsid peptides. Cytotoxicity of T-cell clone produced antigens expressed on the cell surface along
ATC11A to RV capsid peptides was tested in 51Cr release assays using
with major histocompatibility complex (MHC) class I mol-peptide-sensitized autologous EBV-BL AT cells as targets. The peptides
ecules. To determine if the CD8/ T-cell clone ATCGCC(261–277) (m), C(263–275) (l), and C(265–273) (j) were used for
sensitizing target cells in cytotoxicity assays. Unsensitized EBV-BL AT was capable of recognizing endogenously produced and
cells served as controls (h). processed RV antigens, EBV-BL AT cells were infected
with vaccinia recombinant virus expressing RV E1, E2,
or C, vaccinia-RV E1, vaccinia-RV E2, vaccinia-RV C, and
responses in cytotoxicity assays. These mAbs included
wild-type vaccinia virus, which was used as a negative
W6/32 (anti-HLA-A, B and C) (Brodsky and Parham, 1982),
control. The cells infected by recombinant or wild-type
L243 (anti-HLA-DR) (Lampson and Levy, 1980), and IVD12
vaccinia virus were then used as targets in cytotoxicity
(anti-HLA-DQ) (Giles et al., 1983). All mAbs were obtained
assays. The T-cell clone demonstrated cytotoxicity only
from culture supernatants of hybridoma cells purchased
for target cells infected by the vaccinia virus which en-
from the American Type Culture Collection. EBV-BL tar-
codes the C protein containing the sequence C(263–275)
gets were inhibited with anti-HLA mAbs at a dilution of
identified as CD4/ CTL epitope. Hence, these results
1:5 for 30 min before sensitizing with peptide.
suggest that the CD8/ CTL epitope present in the natu-
rally processed RV capsid antigen could be mimicked by
RESULTS AND DISCUSSION
the synthetic peptide C(263–275) (Table 1).
In order to determine the restrictive HLA element,In earlier studies, we used whole inactivated RV or the
capsid peptide C(261–277) to induce RV-specific T-cell murine anti-human HLA class I and II mAbs were used
to inhibit T-cell responses in cytotoxicity assays.lines (Ou et al., 1992a) and clones (Ou et al., 1992b; Ou,
manuscript submitted for publication) from individuals ATCGC cytotoxicity for peptide-sensitized targets was
inhibited only by anti-HLA class I A, B, and C mAb,with different HLA phenotypes. Several CD4/ CTL clones
were identified and characterized. Their responses to with W6/32 confirming HLA class I restriction of the
response (Table 2).peptide C(261–277) and its analogs C(265–273) and
C(263–275) were inhibited by murine monoclonal anti- To identify the exact HLA class I-restrictive molecule,
a panel of 10 EBV-BLs with different HLA phenotypesbody L243 directed to HLA class II DR molecules. More-
over, T-cell clones induced by inactivated whole RV virus was used to provide the target cells in cytotoxicity assays
(Table 3). The results showed that only the vaccinia-RValso recognized peptide C(265–273), indicating that a
naturally processed RV capsid peptide was being mim- C recombinant virus-infected EBV-BLs, RM, MT, and AT
(autologous to the T-cell clone), which have in commonicked by the synthetic peptide (Ou et al., 1992b). The
minimal T-cell epitope recognized by these CD4/ T-cell the HLA class I phenotype, A11 and/or A3, were effective
targets, suggesting that both A3 and A11 class I mole-clones was determined to be C(265–273) (Ou et al.,
1992a,b). Figure 1 shows the specific cytotoxic re- cules were capable of presenting the RV capsid antigen
to clone ATCGC.sponses of one of these clones, ATC11A, to the RV cap-
sid peptide analogs of C(261–277) presented by the EBV- In order to analyze possible anchor residues to HLA
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TABLE 1 tide-specific CTLs, has been recently suggested as a
candidate peptide vaccine for peptide-based therapy onCytotoxicities of the CTL Clone ATCGC DIrected to EBV-BL AT
melanoma patients (Rivoltini et al., 1996; FleischhauerCells Infected with Vaccinia Recombinant Virus Expressing Rubella
Virus Structural Proteins et al., 1996).
Generation of classical CD8/ CTL responses usually
Effector/target ratio requires in vivo priming, either through natural infec-
tion or through vaccination. Synthetic peptides haveInfected virus 10 3 1 0.3
been considered poor immunogens for inducing CD8/
% Specific cytotoxicity a class I-restricted CTLs in vitro. Moreover, several stud-
ies have shown that efficient induction of murine orWild-type vaccinia 0 1.3 2.0 0
human CD8/ cytotoxic T lymphocytes usually requiresVaccinia-RV E1 recombinant 1.3 0.9 0 1.6
antigen-presenting cells and antigen-specific helper TVaccinia-RV E2 recombinant 3.8 0 1.8 0
Vaccinia-RV C recombinant 41.2 33.9 32.9 23.5 cells (Stuhler and Walden, 1993; Celis et al., 1994). It
None 5.2 0 0 0 has also been demonstrated that in vivo induction of
CD8/ cytotoxic T-cell responses by a free synthetica EBV-BL AT cells (autologous to T-cell clone ATCGC) were infected
peptide requires CD4/ T-cell help and that CD4/ Tby virus at 10 PFU/cell for 1 hr, washed three times, incubated over-
cells are necessary to sustain CD8/ T-cell responsesnight, and used as target cells in 51Cr release assays.
during viral infection (Fayolle et al., 1991; Carreno et
al., 1992; Matloubian et al., 1994). Overlapping epi-
topes recognized by CD8/ HLA class I-restricted andA3 and A11 molecules of the T-cell epitope recognized
CD4/ class II-restricted CTLs have been identified inby clone ATCGC, a panel of overlapping peptide analogs
the influenza nucleoprotein peptide, NP(335 – 349)of C(265–273) was prepared and tested for the capacity
(Carreno et al., 1992). This peptide contains two octa-to elicit cytotoxic T-cell responses. The nonamer T-cell
peptide epitopes that share a core of six amino acidepitope inducing the strongest T-cell response among
residues: NP(338 – 343). CD8/ and CD4/ CTL linesthe peptide analogs tested was determined to be C(264–
against NP(335 – 349) were restricted by HLA B37 and272) (Table 4).
DQw5, respectively. Generating HLA B37-restrictedCD8/ CTLs recognize foreign antigen as a peptide
CTL responses to NP(335 – 349) required CD4/ helperfragment bound to an MHC class I molecule. Peptides
T cells which are specific to this peptide and restrictedbinding to human class I molecules are usually 8–10
by DQw5 (Carreno et al., 1992). Epitope linkage is es-residues in length and characteristically have a peptide-
sential for helper T-cell – CTL interaction. Only whenbinding motif containing distinct anchor residues at the
the antigen-presenting cell presents both helper andsecond position from the N-terminal and at the C-termi-
killer epitopes in the context of the corresponding MHCnal position of the sequence (Kubo et al., 1994). However,
restriction elements is it possible for there to be pro-it has been demonstrated that peptides of 13 to 15 resi-
ductive interaction of T cells that results in cytolyticdues can also be recognized by CD8/ T cells as long
activity of CTL (Stuhler and Walden, 1993). Therefore,as they contain the minimal epitope (Achour et al., 1994;
our strategy of using a peptide containing an estab-Robbins et al., 1995). CTL assays using overlapping pep-
lished CD4/ T-cell epitope to induce CD8/ T cells maytide analogs to sensitize the target cells (Table 4) indi-
have been more effective than using a peptide notcated that isoleucine (I) at position 2 from the N-terminal
recognized by CD4/ T cells.in the peptide C(264–272) is likely to be the first anchor
residue and arginine (R) or histidine (H) at the C-terminal
TABLE 2may serve as the second anchor residue. The peptide-
binding motifs of HLA A3 and A11 are very similar (Kubo Inhibition of Rubella Capsid Peptide-Specific Cytotoxic T-Cell
et al., 1994). The arrangement (I at position 2 and R or Responses of Clone ATCGC by Anti-HLA Monoclonal Antibody a
H at position 9 of peptide) is consistent with the peptide-
Anti-HLA % Specificbinding motif predicted for HLA A3 and A11 by Kubo et
specificity cytotoxicity ATCGCal. (1994). Both HLA A3 and A11 are frequently expressed
MAb (dilution 1:5) (Effector/target ratio 3:1)
HLA A alleles (Kubo et al., 1994). The inclusion of epi-
topes recognized by broadly represented HLA class I W6/32 A, B, and C 5.1
L234 DR 28.5and II backgrounds would be desirable to ensure vac-
IVD12 DQ 25.9cine efficacy in individuals with diverse ethnic and HLA
None — 32.8backgrounds (Kubo et al., 1994; Oldstone et al., 1992).
An immunodominant peptide of the human melanoma a EBV-BL AT cells were incubated with mAb, sensitized with the
antigen MT27 – 35 , which could be presented promiscu- peptide RV C(263–275) at concentration of 10 mM for 1 hr, and used
as target cells in 51Cr release assays.ously by six variants of HLA A2 and HLA A*6901 to pep-
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TABLE 3
HLA Class I Subtype Restriction of Cytotoxic Responses of the Rubella Capsid Peptide-Specific T-Cell Clone, ATCGCa
HLA phenotypes of target cells Effector/target ratio
Target
cell A B C DR DQ 10 3 1 0.3
% Specific cytotoxicity
RM 2, 11 13, 16 w3 w9 w3 34.3 26.2 15.3 10.3
w4, w6 w53
CM 1, 32 44, 35 w4 1, 4 w1, w3 0 0.4 0.1 1.4
w6 w53
DO 2 60 w9 w3 0 0.7 4.1 0
w6 w53
HC 24, 30 14, 46 w1, w3 4, w8 w4 0 0 2.9 0.1
w6 w52, w53
MS 2, 24 18, 62 w3 4, w11 w7, w8 0 0 1.5 0
w6 w52, w53
LM 2 35 1, w13 w1 0 0 0 0
w6 w52
AJ 1, 29 8, 45 w6 4, w17 w2, w7 0 0 0 0
w6 w52, w53
RD 2, 19 14, 49 w7 4 w3 0 0 0 0
w4, w6 w53
AT 3, 11 51, 57 w3, w6 4, 7 w3 35.7 29.2 23.1 19.1
w4 w53
MT 2, 3 51, 50 w3 4 w3 (7) 27.5 25.4 18.2 14.0
w4, w6 w53
a EBV-BLs RM, CM, DO, HC, MS, LM, AJ, RD, MT, and AT cells were infected with vaccinia recombinant virus expressing RV capsid protein at
10 PFU/cell overnight and then used as target cells in 51Cr release assays.
A prototypic anti-melanoma vaccine employing a sin- individuals with different HLA phenotypes (Ou et al.,
1992a,b, and manuscript in preparation). The observedgle peptide incorporating both CD4/ and CD8/ T-cell
epitopes has been designed and tested recently (Topal- capacity of RV capsid peptide C(263–275) to elicit both
CD4/ and CD8/ CTL responses here suggests the possi-ian et al., 1996). Our earlier studies have revealed that
RV C(263–275) is likely to be an immunodominant CD4/ bility of using natural overlapping CD4/ and CD8/ epi-
topes for designing a candidate RV peptide-based vac-T-cell epitope recognized promiscuously by T cells from
cine. Future studies will be undertaken to examine the
immunogenicity of this peptide sequence in HLA A3 (or
TABLE 4 A11) transgenic mice.
Identification of the Minimal Epitope Recognized by the CTL Clone
ATCGC within RV C (263–275) ACKNOWLEDGMENTS
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